ASCO 2019: Adding enzalutamide to standard first-line treatment improves survival for men with metastatic hormone-sensitive prostate cancer
An interim analysis of the international randomised, phase III ENZAMET trial found that 80% of…
An interim analysis of the international randomised, phase III ENZAMET trial found that 80% of…
A new blood test for women with breast cancer can predict how well patients will…
The randomised, phase III POLO trial found that maintenance therapy with the PARP inhibitor olaparib…
Nathan Bahary, University of Pittsburgh With Alex Trebek’s recent announcement that his pancreatic cancer is…
Immunotherapy is a revolutionary cancer treatment, but it was unknown if cancer patients with HIV…
A University of Colorado Cancer Center study presented at the American Society for Clinical Oncology…
Crizotinib and entrectinib are both active against ROS1 non-small cell lung cancer. But which is…
Igor Puzanov, MD, Director of the Early Phase Clinical Trials Program and Chief of Melanoma…
Neoadjuvant, or pre-surgical, treatment with nivolumab plus ipilimumab resulted in an overall major pathologic response…
A precision medicine targeting a key protein which helps cancer cells to tolerate DNA damage…